Detection of lung cancer through metabolic changes measured in blood plasma

Journal of Thoracic Oncology

Volumn 11, Issue 4, 2016, Pages 516-523

  Louis, Evelyne ^a   Adriaensens, Peter ^b   Guedens, Wanda ^b   Bigirumurame, Theophile ^a   Baeten, Kurt ^c   Vanhove, Karolien ^a,d   Vandeurzen, Kurt ^d   Darquennes, Karen ^d   Vansteenkiste, Johan ^e   Dooms, Christophe ^e   Shkedy, Ziv ^a   Mesotten, Liesbet ^a,f   Thomeer, Michiel ^a,f  

^a HASSELT UNIVERSITY   (Belgium)

^b HASSELT UNIVERSITY   (Belgium)

^c JANSSEN RESEARCH FOUNDATION   (Belgium)

^d Mariaziekenhuis Noord Limburg ^*  (Belgium)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f DEPARTMENT OF CARDIOLOGY   (Belgium)

Author keywords

1H NMR spectroscopy; Blood plasma biomarker; Lung cancer; Metabolic phenotype; Risk model

Indexed keywords

GLUCOSE; LACTIC ACID; PHOSPHOLIPID; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HUMAN; LACTATE BLOOD LEVEL; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; PHENOTYPE; PHOSPHOLIPID BLOOD LEVEL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SENSITIVITY AND SPECIFICITY; BLOOD; CASE CONTROL STUDY; EARLY CANCER DIAGNOSIS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; COHORT STUDIES; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; METABOLISM; MIDDLE AGED;

EID: 84962921373     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.01.011     Document Type: Article

References (29)

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359-E386.
2. Mulshine JL, Sullivan DC. Clinical practice. Lung cancer screening. N Engl J Med. 2005;352:2714-2720.
3. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Eng J Med. 2011;365:395-409.
4. Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012;307:2418-2429.
5. Hasan N, Kumar R, Kavuru MS. Lung cancer screening beyond low-dose computed tomography: the role of novel biomarkers. Lung. 2014;192:639-648.
6. Cantor JR, Sabatini DM. Cancer cell metabolism: one hallmark, many faces. Cancer Discov. 2012;2:881-898.
7. Munoz-Pinedo C, El Mjiyad N, Ricci JE. Cancer metabolism: current perspectives and future directions. Cell Death Dis. 2012;3:e248.
8. Sciacovelli M, Gaude E, Hilvo M, et al. The metabolic alterations of cancer cells. Methods Enzymol. 2014;542:1-23.
9. Iurlaro R, Leon-Annicchiarico CL, Munoz-Pinedo C. Regulation of cancer metabolism by oncogenes and tumor suppressors. Methods Enzymol. 2014;542:59-80.
10. Upadhyay M, Samal J, Kandpal M, et al. The Warburg effect: insights from the past decade. Pharmacol Ther. 2013;137:318-330.
11. Holmes E, Wilson ID, Nicholson JK. Metabolic pheno-typing in health and disease. Cell. 2008;134:714-717.
12. 1H NMR metabolic profile of human blood plasma and introduction of the standard preanalytical code used in biobanking. Metabolomics. 2015;11:1197-1207.
13. Lindon JC, Nicholson JK. Spectroscopic and statistical techniques for information recovery in metabonomics and metabolomics. Annu Rev Anal Chem. 2008;1:45-69.
14. 1H-NMR: a robust protocol based on metabolite spiking and its evaluation in breast cancer. Metabolomics. 2015;11:225-236.
15. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of Malignant Tumours. J Thorac Oncol. 2007;2:706-714.
16. Louis E, Adriaensens P, Guedens W, et al. Metabolic phenotyping of human blood plasma: a powerful tool to discriminate between cancer types? Ann Oncol. 2016;27:178-184.
17. Wen T, Gao L, Wen Z, et al. Exploratory investigation of plasma metabolomics in human lung adenocarcinoma. Mol Biosyst. 2013;9:2370-2378.
18. Chen Y, Ma Z, Li A, et al. Metabolomic profiling of human serum in lung cancer patients using liquid chromatog-raphy/hybrid quadrupole time-of-flight mass spectrom-etry and gas chromatography/mass spectrometry. J Cancer Res Clin Oncol. 2015;141:705-718.
19. Hori S, Nishiumi S, Kobayashi K, et al. A metabolomic approach to lung cancer. Lung Cancer. 2011;74:284-292.
20. Chen W, Zu Y, Huang Q, et al. Study on metabonomic characteristics of human lung cancer using high resolution magic-angle spinning 1H NMR spectroscopy and multivariate data analysis. Magn Reson Med. 2011;66: 1531-1540.
21. Duarte IF, Rocha CM, Barros AS, et al. Can nuclear magnetic resonance (NMR) spectroscopy reveal different metabolic signatures for lung tumours? Virchows Arch. 2010;457:715-725.
22. Mamas M, Dunn WB, Neyses L, et al. The role of metabolites and metabolomics in clinically applicable bio-markers of disease. Arch Toxicol. 2011;85:5-17.
23. Duarte IF, Rocha CM, Gil AM. Metabolic profiling of bio-fluids: potential in lung cancer screening and diagnosis. Expert Rev Mol Diagn. 2013;13:737-748.
24. Rocha CM, Carrola J, Barros AS, et al. Metabolic signatures of lung cancer in biofluids: NMR-based metabo-nomics of blood plasma. J Proteome Res. 2011;10: 4314-4324.
25. Horeweg N, Scholten ET, de Jong PA, et al. Detection of lung cancer through low-dose CT screening (NELSON): a prespecified analysis of screening test performance and interval cancers. Lancet Oncol. 2014;15:1342-1350.
26. Santos CR, Schulze A. Lipid metabolism in cancer. FEBS J. 2012;279:2610-2623.
27. Baenke F, Peck B, Miess H, et al. Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development. Dis Model Mech. 2013;6:1353-1363.
28. Currie E, Schulze A, Zechner R, et al. Cellular fatty acid metabolism and cancer. Cell Metab. 2013;18:153-161.
29. Leithner K, Hrzenjak A, Trotzmuller M, et al. PCK2 activation mediates an adaptive response to glucose depletion in lung cancer. Oncogene. 2015;34: 1044-1050.